Literature DB >> 9751057

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling.

R B Yang1, M R Mark, A Gray, A Huang, M H Xie, M Zhang, A Goddard, W I Wood, A L Gurney, P J Godowski.   

Abstract

Vertebrates and invertebrates initiate a series of defence mechanisms following infection by Gram-negative bacteria by sensing the presence of lipopolysaccharide (LPS), a major component of the cell wall of the invading pathogen. In humans, monocytes and macrophages respond to LPS by inducing the expression of cytokines, cell-adhesion proteins, and enzymes involved in the production of small proinflammatory mediators. Under pathophysiological conditions, LPS exposure can lead to an often fatal syndrome known as septic shock. Sensitive responses of myeloid cells to LPS require a plasma protein called LPS-binding protein and the glycosylphosphatidylinositol-anchored membrane protein CD14. However, the mechanism by which the LPS signal is transduced across the plasma membrane remains unknown. Here we show that Toll-like receptor 2 (TLR2) is a signalling receptor that is activated by LPS in a response that depends on LPS-binding protein and is enhanced by CD14. A region in the intracellular domain of TLR2 with homology to a portion of the interleukin (IL)-1 receptor that is implicated in the activation of the IL-1-receptor-associated kinase is required for this response. Our results indicate that TLR2 is a direct mediator of signalling by LPS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751057     DOI: 10.1038/26239

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  253 in total

1.  Inhibition of p38 mitogen-activated protein kinase augments lipopolysaccharide-induced cell proliferation in CD14-expressing Chinese hamster ovary cells.

Authors:  D Chakravortty; Y Kato; T Sugiyama; N Koide; M M Mu; T Yoshida; T Yokochi
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 2.  Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity.

Authors:  G Zhang; S Ghosh
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway.

Authors:  E Kopp; R Medzhitov; J Carothers; C Xiao; I Douglas; C A Janeway; S Ghosh
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

4.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 5.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

6.  Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts.

Authors:  K Tabeta; K Yamazaki; S Akashi; K Miyake; H Kumada; T Umemoto; H Yoshie
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Synthesis and surface expression of CD14 by human endothelial cells.

Authors:  H P Jersmann; C S Hii; G L Hodge; A Ferrante
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

8.  Toll receptor-mediated Drosophila immune response requires Dif, an NF-kappaB factor.

Authors:  X Meng; B S Khanuja; Y T Ip
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

Review 9.  Dendritic cells: a link between innate and adaptive immunity.

Authors:  K Palucka; J Banchereau
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

10.  A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster.

Authors:  T Werner; G Liu; D Kang; S Ekengren; H Steiner; D Hultmark
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.